# CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

> **NCT07397832** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 58 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Rituximab
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Chidamide Maintenance

## Key facts

- **NCT ID:** NCT07397832
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2028-07-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07397832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07397832, "CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07397832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*